Ionis Pharmaceuticals, Inc.
IONS
$32.96
$0.060.18%
| Weiss Ratings | IONS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | IONS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | IONS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.65 | |||
| Price History | IONS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -4.16% | |||
| 30-Day Total Return | 3.32% | |||
| 60-Day Total Return | -13.49% | |||
| 90-Day Total Return | -14.96% | |||
| Year to Date Total Return | -4.99% | |||
| 1-Year Total Return | -22.54% | |||
| 2-Year Total Return | -3.60% | |||
| 3-Year Total Return | 0.80% | |||
| 5-Year Total Return | -23.79% | |||
| 52-Week High % Change | -37.03% | |||
| 52-Week Low % Change | 9.03% | |||
| Price | IONS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $52.34 | |||
| 52-Week Low Price | $30.23 | |||
| 52-Week Low Price (Date) | Feb 13, 2025 | |||
| 52-Week High Price (Date) | Jul 26, 2024 | |||
| Valuation | IONS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 5.24B | |||
| Enterprise Value | 4.90B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -3.04 | |||
| Earnings Per Share Growth | 18.79% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 7.39 | |||
| Price/Book (Q) | 8.85 | |||
| Enterprise Value/Revenue (TTM) | 6.94 | |||
| Price | $32.96 | |||
| Enterprise Value/EBITDA (TTM) | -10.57 | |||
| Enterprise Value/EBIT | -10.30 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | IONS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 158.00M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | IONS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 760 931 9200 | |||
| Address | 2855 Gazelle Court Carlsbad, CA 92010 | |||
| Website | www.ionis.com | |||
| Country | United States | |||
| Year Founded | 1989 | |||
| Profitability | IONS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -67.37% | |||
| Profit Margin | -64.37% | |||
| Management Effectiveness | IONS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -9.91% | |||
| Return on Equity | -- | |||
| Income Statement | IONS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 705.14M | |||
| Total Revenue (TTM) | 705.14M | |||
| Revenue Per Share | $4.46 | |||
| Gross Profit (TTM) | -207.61M | |||
| EBITDA (TTM) | -463.13M | |||
| EBIT (TTM) | -475.08M | |||
| Net Income (TTM) | -453.90M | |||
| Net Income Avl. to Common (TTM) | -453.90M | |||
| Total Revenue Growth (Q YOY) | -30.18% | |||
| Earnings Growth (Q YOY) | -1,026.51% | |||
| EPS Diluted (TTM) | -3.04 | |||
| EPS Diluted Growth (Q YOY) | -927.06% | |||
| Balance Sheet | IONS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 2.30B | |||
| Cash Per Share (Q) | $14.58 | |||
| Total Current Assets (Q) | 2.62B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 588.35M | |||
| Current Ratio (Q) | 8.471 | |||
| Book Value Per Share (Q) | $3.73 | |||
| Total Assets (Q) | 3.00B | |||
| Total Current Liabilities (Q) | 309.32M | |||
| Total Debt (Q) | 1.96B | |||
| Total Liabilities (Q) | 2.42B | |||
| Total Common Equity (Q) | 588.35M | |||
| Cash Flow | IONS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -134.03M | |||
| Cash from Financing (TTM) | 478.06M | |||
| Net Change in Cash (TTM) | -157.19M | |||
| Levered Free Cash Flow (TTM) | -352.83M | |||
| Cash from Operations (TTM) | -500.95M | |||
